Biomedical Research

The aim of the current investigation was to scrutinize the protective effect of luteolin against the STZ induced Diabetic Cardiomyopathy (DCM) in rats. The type II diabetes model was selected for the DCM study. In that study, we have used the low dose of the Streptozotocin (STZ) along with the high energy intake. The rats were divided into following groups viz., normal control; STZ induced DCM group, and last one corresponds to the STZ induced DCM treated with luteolin (10 mg/kg). Results of the investigation showed a reduction in fasting blood glucose level, Total Cholesterol (TC) and Triglyceride (TG) in luteolin-treated DCM rats. Moreover, the treatment group showed elevated Body Weight (BW) along with Lower Heart Weight (HW)/BW. Additionally, the luteolin-treated group rats confirmed the decrease the Interventricular Septal Diastolic Wall Thickness (IVSD), Left Ventricular Posterior Wall Thickness (LWPWT), Left Ventricular End-Diastolic Diameter (LVEDD) and increase in Heart Rate (HR). Luteolin also induced the significant improvement in the expression of GSK-3β and phosphorylation of Akt in the myocardium. The findings of the current study suggest that the luteolin might have a beneficial effect against DCM via improvement the Akt/GSK-3β signalling pathway.

Author(s): Yan Zhang, Xiao-Qin Tian, Xiang-Xin Song, Jia-Pu Ge, Yan-Cheng Xu
Abstract | Full-Text | PDF

Share this